Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance
Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance
复制标题
DOI：
10.1159/000081973
复制
发表时间：
2004-01-01
期刊：
影响因子：
--
通讯作者：
Aslan, C
中科院分区：
文献类型：
--
作者：
Bahceci, M;Tuzcu, A;Aslan, C
背景/目的：胰岛素抵抗与血清c反应蛋白（CRP）水平相关。我们旨在评估比卡鲁胺对非肥胖型多囊卵巢综合征（PCOS）患者胰岛素抵抗和血清CRP水平的影响。方法：选取40例体重指数小于或等于25 kg/m(2)的非肥胖多囊卵巢综合征患者和40例年龄和体重指数匹配的健康女性为研究对象。患者口服比卡鲁胺，剂量为25mg /天。采用免疫测定法测定血清CRP水平。胰岛素抵抗采用稳态模型评估（HOMA-IR）指数。结果：PCOS患者的平均Ferriman-Gallwey评分（FGS） （p = 0.001）、胰岛素（p = 0.001）、血糖（p = 0.001）、催乳素（p < 0.003）、总睾酮（p < 0.04）、游离睾酮（p = 0.001）和游离雄激素指数（FAI）水平（p = 0.001）均高于对照组。PCOS患者的平均HOMA-IR高于对照组（2.43 +/- 1.2和0.94 +/- 0.37,p = 0.001）。PCOS患者的CRP水平也高于对照组（4.27 +/- 1.33和0.98 +/- 0.19,p = 0.001）。比卡鲁胺治疗后，FGS、游离睾酮和总睾酮及FAI降低（p = 0.001）。比卡鲁胺治疗组HOMA-IR、催乳素和CRP水平无统计学差异。结论：PCOS患者存在胰岛素抵抗和高CRP水平。比卡鲁胺治疗不影响多囊卵巢综合征的胰岛素抵抗和CRP水平，比卡鲁胺对CRP水平的无效可能是此时胰岛素抵抗和/或高催乳素水平的结果。版权所有(C) 2004 S. Karger AG，巴塞尔。
Background/Aims: Insulin resistance is associated with serum C-reactive protein (CRP) levels. We aimed to evaluate the effect of bicalutamide on insulin resistance and serum CRP levels in non-obese polycystic ovarian syndrome (PCOS) patients. Methods: 40 non-obese patients (BMI less than or equal to25 kg/m(2)) with PCOS and, 40 age- and BMI-matched healthy women were studied. Patients received bicalutamide orally at the dose of 25 mg/day. Serum CRP levels were measured with immunometric assay. Homeostasis model assessment (HOMA-IR) index was used for insulin resistance. Results: Mean Ferriman-Gallwey score (FGS) (p = 0.001), insulin (p = 0.001), serum glucose (p = 0.001), prolactin (p < 0.003), total (p < 0.04) and free testosterone (p = 0.001) and free androgen index (FAI) levels (p = 0.001) of PCOS subjects were higher than in the control group. Mean HOMA-IR of PCOS patients was higher than in control subjects (2.43 +/- 1.2 and 0.94 +/- 0.37, p = 0.001). CRP levels in subjects with PCOS was also higher than in control subjects (4.27 +/- 1.33 and 0.98 +/- 0.19, p = 0.001). After bicalutamide treatment, FGS, free and total testosterone and FAI decreased (p = 0.001). HOMA-IR, prolactin and CRP levels did not show any statistical difference with bicalutamide treatment. Conclusions: PCOS patients had insulin resistance and a high CRP level. Bicalutamide treatment did not influence insulin resistance and CRP level in PCOS, and this ineffectiveness of bicalutamide on CRP levels may be the result of insulin resistance and/or high prolactin levels at this time. Copyright (C) 2004 S. Karger AG, Basel.